Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
Operating Margin for Fusion Antibodies plc (FAB)
Operating Margin as of September 2026 TTM: -118.73%
According to Fusion Antibodies plc latest financial reports and stock price the company's current Operating Margin (TTM) is -118.73%. At the end of 2024 the company had an Operating Margin of -201.41%.
Operating Margin history for Fusion Antibodies plc from 2013 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -118.73% 31.15%
2025 -90.53% -55.05%
2024 -201.41% 106.24%
2023 -97.66% 251.80%
2022 -27.76% -16.16%
2021 -33.11% 15.77%
2020 -28.60% -58.63%
2019 -69.14% -3,080.17%
2018 2.32% -64.90%
2017 6.61% 253.48%
2016 1.87% -117.22%
2015 -10.86% -34.26%
2014 -16.52% -85.86%
2013 -116.84% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.24%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -98.74%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -100.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.